Antiparasitic Efficacy of Curcumin Against Besnoitia besnoiti Tachyzoites in vitro

María Eugenia Cervantes-Valencia1*, Carlos Hermosilla2, Yazmin Alcalá-Canto3, Graciela Tapia4, Anja Taubert2 and Liliana M. R. Silva2*

1 Graduate Program of Animal Health and Production, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Mexico City, Mexico, 2 Institute of Parasitology, Justus Liebig University Giessen, Giessen, Germany, 3 Department of Parasitology, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Mexico City, Mexico, 4 Department of Genetics and Biostatistics, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Mexico City, Mexico

Besnoitia besnoiti is the causative agent of bovine besnoitiosis. B. besnoiti infections lead to reduced fertility and productivity in cattle causing high economic losses, not only in Europe, but also in Asia and Africa. Mild to severe clinical signs, such as anasarca, oedema, orchitis, hyperkeratosis, and characteristic skin and mucosal cysts, are due to B. besnoiti tachyzoite and bradyzoite replication in intermediate host tissues. So far, there are no commercially available effective drugs against this parasite. Curcumin, a polyphenolic compound from Curcuma longa rhizome is well-known for its antioxidant, anti-inflammatory, immunomodulatory and also anti-protozoan effects. Hence, the objective of this study was to evaluate the effects of curcumin on viability, motility, invasive capacity, and proliferation of B. besnoiti tachyzoites replicating in primary bovine umbilical vein endothelial cells (BUVEC) in vitro. Functional inhibition assays revealed that curcumin treatments reduce tachyzoite viability and induce lethal effects in up to 57% of tachyzoites (IC50 in 5.93 µM). Referring to general motility, significant dose-dependent effects of curcumin treatments were observed. Interestingly, curcumin treatments only dampened helical gliding and twirling activities whilst longitudinal gliding motility was not significantly affected. In addition, curcumin pretreatments of tachyzoites resulted in a dose-dependent reduction of host cell invasion as detected by infections rates at 1 day p. i. These findings demonstrate feeding cattle with Curcuma longa rhizomes may represent a new strategy for besnoitiosis treatment.

Keywords: curcumin, Besnoitia besnoiti, bovine besnoitiosis, antiparasitic effect, in vitro, tachyzoite

INTRODUCTION

Besnoitia besnoiti (phylum Alveolata, subphylum Apicomplexa, family Sarcocystidae) is an intracellular obligate parasite infecting cattle phylogenetically closely related to Toxoplasma gondii and Neospora caninum (1, 2).

Bovine besnoitiosis, which is an emergent disease in Europe but is also vastly endemic in Asia and Africa, causes considerable economic losses in cattle industry (1). Even though a high percentage of B. besnoiti-infected animals are commonly asymptomatic, some of them show mild to severe disease. Thus, during the acute phase of bovine besnoitiosis, fast replication of tachyzoites
in host endothelial cells of different organs and vessels causes severe symptoms such as fever, nose and eye discharge, photophobia and anasarca, accepting a variable clinical prevalence of between 1 and 10% in endemic herds. Nevertheless, the mortality rate depends on whether besnoitiosis is endemic or epidemic (2). During the chronic phase of infection, slow replicating bradyzoites induce the formation of large-sized thick-walled cysts mainly found in subcutaneous tissues and mucous membranes (1). Furthermore, decline in milk, and infertility (temporary or permanent) in bulls due to orchitis are observed (3). Presently, the complete life cycle of *B. besnoiti* is not entirely solved and especially final host species are still unknown. Nevertheless, direct contact between infected and non-infected animals (e.g., natural mating, naso-pharyngeal route) and insect-mediated transmission (i.e., tabanids, *Stomoxys calcitrans*) (2, 4) have been suggested as suitable transmission routes. Hence, to prevent and avoid rapid spreading of the disease in Europe, effective treatment and diagnostic measures are urgently needed. So far, diagnosis of cattle besnoitiosis is mainly based on the occurrence of typical cystic lesions on scleral conjunctiva or dermis and on serological tools (i.e., ELISA and western blot) (2, 5).

So far, no effective treatment against *Besnoitia* spp. is commercially available (1). In the last years, several drugs such as nitazoxanide, tizoxanide, sulfadiazine, thiazolides, biphenylimidazoazines, bumped kinase inhibitors (BKIs), diclazuril, decoquinato, and naphto-quinone buparvaquone have been tested for their efficacy against *Besnoitia* spp. (6–11). Furthermore, no vaccines against cattle besnoitiosis are licensed in Europe (2), even though the usage of recently tested live and attenuated vaccines could increase the risk of introducing the parasite into non-infected herds and of having carrier animals in the herds (1). Consequently, there is an urgent need for alternative control measures for bovine besnoitiosis.

Curcumin is a polyphenol present in the *Curcuma longa* rhizome and it has been widely used for centuries both as a spice or in traditional medicine based on its well-known anti-oxidant and anti-inflammatory properties (12). More recently, several investigations have proven that curcumin also exhibits anti-parasitic effects (13). In times of increasing resistance of several parasites against synthetic antiparasitic drugs worldwide, which imposes a huge problem in livestock production (14, 15), the application of bioactive plant compounds represent an important alternative measure to control parasitoses (16–18). Therefore, in *in vitro* anti-protozoan effects of curcumin against numerous species have recently been described, i.e., *Eimeria tenella*, *E. bovis*, *Giardia intestinalis*, *Plasmodium falciparum*, *P. berghei*, *Leishmania* spp., *Trypanosoma cruzi*, *T. evansi*, *Cryptosporidium parvum*, *Neospora caninum*, and *Toxoplasma gondii* (19–26). In addition, *in vivo* effects of curcumin treatments were also documented in rabbit and sheep coccidiosis (27, 28). Overall, the molecular mechanism of curcumin action is not known so far, but interference with intracellular organelles and cytoskeleton or with cellular metabolism is postulated (29), which might impact on protozoan parasites. Furthermore, curcumin inhibits the glyoxalase system of *T. gondii* (24) and efficiently blocks histone deacetylation in curcumin-exposed *P. falciparum* (25).

The aim of the current study was to evaluate the effects of curcumin on the viability and motility of *B. besnoiti* tachyzoites, as well as to determine its impact on tachyzoite host cell invasion and intracellular parasite proliferation in primary bovine host endothelial cells *in vitro*.

**MATERIALS AND METHODS**

**Parasites**

*B. besnoiti* (strain Eb1Evora04) was maintained by several passages of tachyzoites in primary bovine umbilical vein endothelial cells (BUVEC) according to previous reports (30). Freshly released tachyzoites were collected from cell culture supernatants, filtered with a 5 µm syringe filter (Sartorius®), centrifuged (350 × g, 12 min), counted (Neubauer chamber), and then suspended in modified endothelial cell growth medium [ModECGM; ECGM (PromoCell®) mixed with 70% (v/v) M199 (Sigma-Aldrich®), 10% fetal calf serum (FCS; Gibco®) and 1% penicillin-streptomycin (PS; Sigma-Aldrich®)] shortly before usage.

**Host Cells**

Primary BUVEC were isolated according to Taubert et al. (31) and cultured in ModECGM. Cell culture medium was changed every 2 days until cells reached 80% confluency. To determine the influence of treatments on infection and proliferation capacities of parasites, different BUVEC isolates (*n* = 3, 12-well formats, Greiner) were cultured for 24 h and 48 h (37°C, 5% CO₂) after *B. besnoiti* tachyzoite infection. BUVEC cell layers were used for infection after 2–3 passages in *in vitro*.

**Effects of Curcumin on *B. Besnoiti* Tachyzoite Viability and Motility**

For all *in vitro* studies, a stock solution of 20 mM curcumin (Sigma-Aldrich®, C1386) in DMSO (dimethyl sulfoxide, Sigma-Aldrich®) was prepared and used for different dilutions (1, 2, 4, and 8 µM) in ModECGM. Plain medium (ModECGM) and medium containing DMSO (DMSO, 1:2,500) were used as medium and solvent controls, respectively.

For viability-related experiments, 5 × 10⁶ tachyzoites were incubated for 90 min with increasing doses of curcumin (1, 2, 4, 8 µM; 5% CO₂, 37°C). Viability of tachyzoites was determined by the trypan blue (Sigma-Aldrich®) staining assay (19). Unstained parasites were considered as viable.

Motility tests were performed according to a previous report on *T. gondii* tachyzoites (32). The same number of tachyzoites, doses of curcumin, and incubation time were used as in viability experiments. After incubation, tachyzoites were washed twice in plain medium to remove any traces of curcumin or DMSO. To assess the effects of curcumin on tachyzoites motility, five different vision power fields per treatment (50–60 tachyzoites per condition) were randomly recorded for 2 min each using an invorted microscope (IX81, Olympus®) equipped with a XM10 camera (Olympus®), in 12-well cell culture plates and analyzed later on. Different types of movements were observed and quantified: general motility (any movement), gliding motility (or
longitudinal gliding), twirling and helical-gliding, as previously described (33).

Cytotoxicity of Curcumin for Host Endothelial Cells
In order to determine if curcumin had cytotoxic effects on BUVEC, XTT cell viability assays (CyQUANT™, Invitrogen) were performed. Therefore, a total of $5 \times 10^5$ BUVEC/well were seeded (96 well-plate) and cultured at $37^\circ C$, 5% CO$_2$ until confluency. Increasing concentrations of curcumin (0.25, 0.50, 1, 2, 4, 8, and 16 μM) were added to BUVEC and incubated for 90 min and 180 min. Thereafter, XTT cell viability assays were performed according to the manufacturer’s instructions. Plain medium and DMSO-supplemented medium (1:2,500) were used as controls.

Effects of Curcumin on B. Besnoiti Tachyzoite Host Cell Invasion and Intracellular Proliferation
Following pretreatments (90 min; 1–8 μM curcumin, 37°C, 5% CO$_2$), B. besnoiti tachyzoites were washed twice in ModECGM to remove any curcumin/DMSO residues. Confluent BUVEC ($n = 3$) were infected with pre-treated tachyzoites (curcumin) or non-treated control parasites (ModECGM, DMSO) at a multiplicity of infection (MOI) of 1:4. At 24 h post infection (p. i.), infection rates were determined microscopically by counting infected and non-infected BUVEC in 16 visual power vision fields (400 x) per treatment. After 48 h p. i., freshly released tachyzoites were collected from cell culture supernatants, centrifuged (350 x g, 12 min) and counted using a Neubauer chamber to determine the proliferation capacity of pre-treated B. besnoiti tachyzoites.

Statistical Analysis
IC$_{50}$, IC$_{90}$, and IC$_{99}$ values (concentrations which inhibit 50, 90, and 99% tachyzoite survival) were calculated by probit regression analyses for viability assay. For motility/movement assays, a univariate analysis of variance was performed and multiple comparison tests were applied (Tukey or Dunn’s, general motility and type of movement, respectively). Normal distribution of the data was confirmed for infection rate (%) data with Shapiro-Wilk Test ($p > 0.05$). The data were then analyzed by a general linear model with treatment [control, DMSO and curcumin (1, 2, 4, and 8 μM)] as fixed factor and BUVEC cells as random factor, with least square means method. Given that the data of tachyzoites production showed a Poisson distribution, they were analyzed by a generalized linear model (GzLM) with maximum-likelihood as method of estimation, applying link log and Poisson distribution. The marginal means were estimated for each treatment and compared by pairs of groups by Bonferroni test. Statistical analyses were performed using SPSS software (IBM SPSS® Statistics) version 21. Significant statistical differences were considered at $p < 0.05$.

RESULTS

Curcumin Treatments Impair B. Besnoiti Tachyzoite Viability
Treatments with 1, 2, 4, and 8 μM curcumin led to an enhanced tachyzoite mortality rate of 21.3, 34.7, 38.7, and 57%, respectively (Table 1). In contrast, in medium and solvent controls, a mortality rate of 6 and 12% was observed, respectively. Overall, curcumin treatments resulted in dose-dependent lethal effects on B. besnoiti tachyzoites probit regression was significant at $p = 0.0001$ Zc = 9.31; IC$_{50}$, IC$_{90}$, and IC$_{99}$ were 5.93, 112.59, and 1240.35 μM, respectively (Table 1). Upon curcumin exposure (90 min), tachyzoites lost their characteristic half-moon- or banana-shape form, presenting a blunt tip at the apical edge. In addition, the tachyzoite pellicula appeared affected and showed an irregular morphology (data not shown).

Curcumin Treatments Affect B. Besnoiti Tachyzoite Motility
Tachyzoites were considered as immobilized when they failed to move during the entire observation period of 2 min. Overall, a significantly reduced general motility of tachyzoites was detected at curcumin concentrations of 4 μM ($p = 0.027$) and 8 μM ($p = 0.0001$) when compared to negative controls (please also refer to Video 1 in Supplementary Material). Broken down on the three different types of movement, twirling and helical gliding were significantly reduced at 8 μM curcumin treatments ($p = 0.0159$, $p = 0.0135$, respectively) whilst gliding motility was not significantly affected (Figure 1).

Curcumin Pretreatments Block B. Besnoiti Tachyzoite Host Cell Invasion
As an obligate intracellular parasite, B. besnoiti needs to actively invade host endothelial cells in vivo in order to successfully replicate and to complete its life cycle. Infection rates were determined at 24 h p. i., when typical meront stages containing rosettes structures with newly formed tachyzoites (white arrows, Figure 2) are present in host cells. Overall, curcumin pretreatments of tachyzoites led to a significant reduction of infection rates in BUVEC ($p < 0.0001$) in vitro (Figure 2E). As such, medium- and solvent-treated tachyzoites invaded BUVEC at a high percentage and led to an infection rate of 63.5 and 67.5%. In contrast, host cell infections with curcumin-treated tachyzoites resulted in the following infection rates: 1 μM (62.10%), 2 μM (58.69%), 4 μM (1.48%), and 8 μM (1.61%). Significant differences were observed at 4 and 8 μM curcumin treatments (both, $p < 0.0001$). Additionally, cytotoxicity assay (XTT) revealed that concentrations higher than 8 μM curcumin (percentage of control) resulted in adverse effects on exposed BUVEC (please refer to Figure 1 in Supplementary Material; IC$_{50}$ 6.3 μM). In all experiment settings, treated-tachyzoites were always washed after the incubation period (90 min), reducing significantly the amount of curcumin that the host cells could eventually being exposed to, confirming that inhibition of invasion was not due to any curcumin-derived cytotoxic effect.
TABLE 1 | Effects of curcumin treatments on *B. besnoiti* tachyzoite viability.

| Dose   | Mortality (%) | IC₉₀ (µM) (LL, UL) | IC₉₀ (µM) (LL, UL) | IC₉₀ (µM) (LL, UL) | \( \chi^2 \) (P) |
|--------|---------------|-------------------|-------------------|-------------------|------------------|
| Medium control | –             | 6.50 (4.87, 7.75) | 112.59 (58.22, 306.96) | 1240.35 (425.16, 6372.65) | 6.97 (0.72) |
| Solvent control | –             | 12.05             |                   |                   |                  |
| Curcumin 1 µM | 21.32         |                   |                   |                   |                  |
| 2 µM     | 34.72         |                   |                   |                   |                  |
| 4 µM     | 38.70         |                   |                   |                   |                  |
| 8 µM     | 56.97         |                   |                   |                   |                  |

IC, inhibitory concentration; LL, lower limit; UL, upper limit.

---

**Curcumin Hampers *B. Besnoiti* Tachyzoites Replication in BUVEC**

Curcumin treatments had a considerable effect on intracellular parasite proliferation. As such, a significant decrease of newly released *B. besnoiti* tachyzoite numbers was observed in curcumin-treated groups at 48 h p. i. when compared to non-treated controls (Figure 2E). As such, significant differences (all \( p < 0.0001 \)) in tachyzoite replication were detected between the solvent control (3.53 × 10⁹ ± 7.23 × 10⁸) and 1 µM (1.09 × 10⁷ ± 2.51 × 10⁶), 2 µM (1.35 × 10⁶ ± 2.28 × 10⁵), 4 µM (2.31 × 10⁴ ± 1.63 × 10³), and 8 µM (0.00 ± 0.00) treatments. It appears obvious that less tachyzoites are produced if initial infection rates are lower (Figure 2E). However, given that infection rates were not affected in the case of 1 and 2 µM treatments (Figure 2E), the antiproliferative effects of curcumin at these doses must be related to compound-induced impairment of parasite replication thus proving that curcumin indeed impairs *B. besnoiti* intracellular replication in primary host endothelial cells.

**DISCUSSION**

Bovine besnoitiosis is spreading in Europe (34, 35), but also in other continents, such as Africa and Asia. Nonetheless, no commercial drugs against *B. besnoiti* are currently available; thus efforts on alternative effective control strategies are urgently needed to prevent further spread of this disease. In the recent years, several synthesized compounds have been tested against *B. besnoiti in vitro*, e.g., nitazoxanide, tizoxanide and sulfadiazine, thiazolides, biphennylimidazoazoles, bumped kinase inhibitors (BKIs), diclazuril, decoquinate, and naphtho-quinone buparvaquone (6–11). In a new *in vitro* study, well-known anticoccidial drugs such as decoquinate and diclazuril showed to inhibit infection rates by 90 and 83% at 0 h p. i., respectively (14). Even though repurposing of commercially available anticoccidial drugs is a reasonable strategy for identifying therapeutic compounds against *B. besnoiti*, during the last decades, the abuse and massive usage of anticoccidial drugs for control of other apicomplexan parasites (i.e., *Eimeria*, *Sarcocystis*, *Cystoisospora*, *Neospora*) has generated the development of parasite resistances against these commercial compounds. In general, anticoccidial drugs are known to hamper development of intracellular parasite stages (sporozoites, trophozoites, merozoites, gametocytes), and most of them can be administrated as food additives or diluted in drinking water. Starting in the 1960s and until now, resistance to anticoccidian drugs has been increasing and it has been reported to occur largely in chicken and swine industries due to inadequate or abuse drug usage (33, 36–38). Since 2006, the European Union (EU) has strictly limited the usage of chemical anticoccidian compounds as food/water additives even proposing an entire ban from 2021 onwards (Council Directive of 2011/50/EU of The European Council) to prevent residues of coccidiostatics in animal products (39). Therefore, usage of alternative bioactive plant compounds with natural anticoccidial efficacies represent a good alternative to synthetic drugs. So far, few herbal-based anticoccidial compounds are available on the market, especially to be used as food additives in poultry and other industries...
FIGURE 2 | Effects of curcumin pretreatments of *Besnoitia besnoiti* tachyzoites on infection rate and parasite proliferation in bovine endothelial host cells. *B. besnoiti* tachyzoites were pretreated with different doses of curcumin (1, 2, 4, and 8 µM) for 90 min and used for bovine umbilical vein endothelial cell (BUVEC) infection (for illustrations, see (A–D), bar 50 µm). At 24 h p. i., infection rates were determined microscopically (E) and at 48 h p. i. tachyzoite production was analyzed (F) (**p < 0.0001).

(13). Using anticoccidial bioactive plant compounds as food supplements will further facilitate the administration process and avoid extra animal handling for treatments.

Curcumin is a polyphenol from *C. longa* rhizome with antioxidant and antiparasitic effects. As such, *Eimeria*-infected animals showed diminished oocysts shedding and less lesions after curcumin treatment (19, 27, 40, 41). More importantly, daily weight gains revealed two-fold higher in curcumin-treated farm animals compared to non-treated controls (28). In addition, curcumin treatments also resulted in improved quality of meat products (prolonged storage stability), most probably due to antioxidant activities of curcumin (42). Curcumin also has immunomodulatory properties in vivo, as shown by COX-2 downregulation and inhibition of pro-inflammatory enzymes, such as LOX-5 and iNOS. It furthermore inhibits the production of important pro-inflammatory cytokines, such as TNF-α and IFN-γ, the latter one by suppressing JAK-STAT- and NF-κB-related signaling cascades (43, 44).

In the current study, the efficacy of curcumin against tachyzoites of *B. besnoiti* is demonstrated in vitro for the first time. The natural compound curcumin led to reduce *B. besnoiti* tachyzoite viability, with up to 56% mortality (IC$_{50}$ 5.93 µM) in treated tachyzoites. In line with these findings, studies using lower doses of synthesized compounds such as decoquinate, diclazuril (14), and naptho-quinone buparvaquone (13) also exhibited promising in vitro activities against *B. besnoiti* as the
showed a loss of integrity and viability (cells drastically dropped in curcumin-treated groups. Similarly, capacity significantly reduced tachyzoite general motility and invasion of host cells, most probably due to pivotal role in apicomplexan motility, whilst twirling of tachyzoites whilst gliding motility was not altered. Gliding motility allows for movement across cell surfaces and for dissemination within the host and is also a prerequisite for tachyzoite cell invasion, since it provides the force for the active invagination of the host cell membrane. Whilst twirling allows the parasite to position itself to successfully invade a host cell, helical gliding represents a more progressive type of tachyzoite locomotion allowing the parasite to traverse longer distances of 10–200 µm within the host (32), most probably in search of adequate host cells. Here, helical gliding and twirling were significantly reduced. Therefore, alterations of motility caused by higher concentrations of curcumin, were correlated with lower infection rates with the same treatments.

Overall, the current findings proved that curcumin as a natural, plant-derived compound exhibits anticoccidial activity against B. besnoiti tachyzoites in vitro. Thus, it is reasonable to assume that curcumin/C. longa could represent an effective alternative to synthetic chemical compounds for the control of B. besnoiti in bovines and maybe also other hosts suffering besnoitiosis (e.g., goats, equids, rabbits, reindeers). However, the lack of a suitable in vivo model of besnoitiosis complicates the so needed further in vivo experiments to increase the knowledge on pharmacokinetics, bioavailability and pharmacodynamics of curcumin. Nevertheless, the low costs and convenience of curcumin production offers this compound as a rather cheap resource for low-income cattle or other livestock industries worldwide, especially in Africa, South America, and Asia.

**AUTHOR CONTRIBUTIONS**

MC-V, LS, CH, and AT designed the experiments. MC-V and LS performed the experiments. YA-C, GT, MC-V, and LS analyzed and interpreted data. MC-V, LS, CH, and AT wrote and edited the manuscript. All authors approved the final version of the manuscript.

**ACKNOWLEDGMENTS**

We would like to acknowledge Brigitte Hofmann and Dr. Christin Ritter for the outstanding work in cell culture. This study was supported by the scholarship 378283 granted by the Consejo Nacional de Ciencia y Tecnología (CONACYT).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fvets.2018.00333/full#supplementary-material
REFERENCES

1. Cortes H, Leitão A, Gottstein B, Hemphill A. A review on bovine besnoitiosis: a disease with economic impact in herd health management, caused by Besnoitia besnoiti (Franco and Borges). Parasitology (2014) 141:1406–17. doi: 10.1017/S0031182014002620

2. Gutiérrez-Expósito D, Ferre L, Ortega-Mora LM, Álvarez-García G. Advances in the diagnosis of bovine besnoitiosis: current options and applications for control. Int J Parasitol. (2017) 47:737–51. doi: 10.1016/j.ijpara.2017.08.003

3. Olias P, Schade B, Mehnhir H. Molecular pathology, taxonomy and epidemiology of Besnoitia species (Protozoa: Sarcocystidae). Infect Genet Evol. (2011) 11:1564–76. doi: 10.1016/j.meegid.2011.08.006

4. Gollnick NS, Scharr JC, Schares G, Langenmayer MC. Natural Besnoitia besnoiti infections in cattle: chronology of disease progression. BMC Vet Res. (2015) 11:1–16. doi: 10.1186/s12917-015-0344-6

5. García-Lunar P, Ortega-Mora LM, Schares G, Diezma-Díaz C, Álvarez-García G. A new lyophilized tachyzoite based ELISA to diagnose Besnoitia infection in bovins and wild ruminants improves specificity. Vet Parasitol. (2017) 244:176–82. doi: 10.1016/j.vetpar.2017.07.029

6. Cortes HC, Mueller N, Esposito M, Leitão A, Naguleswaran A, Hemphill A. In vitro efficacy of nitro- and bromo-thiazolyl-salicylamide compounds (thiazolides) against Besnoitia besnoiti infection in vero cells. Parasitology (2007) 134:975–85. doi: 10.1017/S0031182007002417

7. Elsheikha HM, Mansfield LS. Determination of the activity of sulfadiazine for the first time in the United Kingdom. Vet Res. (2014) 105:1155–61. doi: 10.1007/s00436-009-1353-5

8. Goo Y, Yamagishi I, Ueno A, Terkawi MA, Aboge GO, Kwak D, et al. Characterization of Toxoplasma gondii glyoxalase I and evaluation of inhibitory effects of curcumin on the enzyme and parasite cultures. Parasit Vectors (2015) 8:654. doi: 10.1186/s13071-015-1268-5

9. Cui L, Xiao J, Cui L. Cytotoxic effect of curcumin on malaria parasite Plasmodium falciparum: inhibition of histone acetylation and generation of reactive oxygen species. Antimicrob Agents Chemother. (2007) 51:488–94. doi: 10.1128/AAC.01238-06

10. Cervantes-Valencia ME. Evaluación Etiopatógenica de la Curcumína (Curcuma longa) en Orígenes Estabulados Infetados con Eimeria spp. (2016) Available online at: http://tr.vamex.mx/bitstream/handle/20.500.11799/65157/2016%20-%20MORA%20C%20EGUIX%20CERVANTES%20VALENCIA-lovepdf-compressed-split-merge.pdf?sequence=3&extracted=1

11. Cervantes-Valencia ME, Alcalá-Canto Y, Salem AZM, Kholf AE, Ducoing-Watty AM, Bermond-Bermad ML, Gutiérrez-Olvera C. Influence of curcumin (Curcuma longa) as a natural anticoccidial alternative in adult rabbits: first results. Ital J Anim Sci. (2015) 14:13–7. doi: 10.4081/ijas.2015.3838

12. Cervantes-Valencia ME, Alcalá-Canto Y, Sumanon-Lopez H, Ducoing-Watty AM, Gutiérrez-Olvera L. Effects of Curcuma longa dietary inclusion against Eimeria spp. in naturally-infected lambs. Small Rumin Res. (2016) 135:27–35. doi: 10.1016/j.smallrumres.2015.12.035

13. Gutiérrez-Gutiérrez F, Palomo-Liga Z, Hernández-Herrández JM, Pérez-Rangel A, Aguayo-Ortiz R, Hernández-Campos A, et al. Curcumin alters the cytokine and microtubule organization in tropheozoids of Giardia lamblia. Acta Trop. (2017) 172:113–21. doi: 10.1016/j.actatropica.2017.04.027

14. Muñoz-Caro T, Silva LMR, Ritter C, Taubert A, Hermosilla C. Besnoitia besnoiti tachyzoites induce monocyte extracellular trap formation. Parasitol Res. (2014) 113:4189–97. doi: 10.1007/s00436-014-4094-3

15. Taubert A, Zahner H, Hermosilla C. Dynamics of transcription of immunomodulatory genes in endothelial cells infected with different coccidial parasites. Vet Parasitol. (2006) 142:214–22. doi: 10.1016/j.vetpar.2006.07.021

16. Håkansson S, Morisaki S, Koibenn J, Sibley LD. Time-lapse video microscopy of gliding motility in Toxoplasma gondii reveals a novel, biphasic mechanism of cell locomotion. Mol Biol Cell (2019) 10:5359–47. doi: 10.1091/mbc.11.5359

17. Warren EW, Ball SJ, Mackenzie DR. The incidence of drug resistant strains of Eimeria species in chickens in Great Britain, 1964/65. (1966) Br Vet J. 122:534–43. doi: 10.1016/S0007-1933(17)4256-9

18. EFSA European Food Safety. Bovine besnoitiosis: an emerging disease in Europe. EFSA J. (2010) 8:1499. doi: 10.2903/j.efsa.2010.1499

19. Gollnick NS, Scharr JC, Schares G, Bärdwald A, Schares G, Langenmayer MC. Naturally acquired bovine besnoitiosis: disease frequency, risk and outcome in an endemically infected beef herd. Transbound Emerg Dis. (2018) 65:833–43. doi: 10.1111/tbed.12810

20. Chapman HD. Resistance of field isolates of Eimeria species to anticoccidial drugs. Avian Pathol. (1976) 5:283–90. doi: 10.1080/0307945760841897

21. Witcombe DM, Smith NC. Strategies for anti-coccidial prophylaxis. Parasitology (2014) 141:1379–89. doi: 10.1017/S0031182014000195

22. Ahmad TA, El-sayed BA, El-sayed LH. Development of immunization trials against Eimeria spp. TRIALS Vaccinol. (2016) 5:38–47. doi: 10.1186/tvacinol.2016.02.001

23. Serrato J, Blass A, Rigau B, Mongrell B, Rigau T, Tortadés M, et al. Residues from veterinary medicinal products, growth promoters and performance enhancers in food-producing animals: a European Union perspective. Rev Sci Tech. (2006) 25:637–53.
40. Kim DK, Lillegard HS, Lee, SH, Jang SI, Lillegard EP, Bravo D. Dietary Curcuma longa enhances resistance against Eimeria maxima and Eimeria tenella infections in chickens. Poult Sci. (2013) 92:2635–43. doi: 10.3382/ps.2013-03095

41. Peek HW, Halkey SR, Mes JJ, Landman WJM. In vivo screening of four phytochemicals/extracts and a fungal immunomodulatory protein against an Eimeria acervulina infection in broilers. Vet Q. (2013) 33:132–8. doi: 10.1080/01652176.2013.844378

42. Rajput N, Ali S, Naeem M, Khan MA, Wang T. The effect of dietary supplementation with the natural carotenoids curcumin and lutein on pigmentation, oxidative stability and quality of meat from broiler chickens affected by a coccidiosis challenge. Br Poult Sci. (2014) 55:501–9. doi: 10.1080/00071668.2014.925537

43. Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, Priyadarsini IK, et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep. (2011) 28:1937–55. doi: 10.1039/c1np00051a

44. Sandur SK, Pandey MK, Sung B, Ahn KS, Murakami A, Sethi G, Limtrakul P, et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis (2007) 28:1765–73. doi: 10.1093/carcin/bgm123

45. Panahi Y, Atkin SL, Butler AE, Johnston TP. Evidence of curcumin and curcumin analogue effects in skin diseases: a narrative review. J Cell Physiol. (2018) 234:1653–78. doi: 10.1002/jcp.27096

46. Fu C, Ding C, Sun X, Fu A. Materials Science & Engineering C Curcumin nanocapsules stabilized by bovine serum albumin-capped gold nanoclusters ( BSA-AuNCs ) for drug delivery and theranosis. Mater Sci Eng C (2018) 87:149–54. doi: 10.1016/j.msec.2017.12.028

47. Reddy RC, Vatsala PG, Keshamouni VG, Padmanaban G, Rangarajan PN. Curcumin for malaria therapy. Biochem Biophys Res Commun. (2005) 326:472–4. doi: 10.1016/j.bbrc.2004.11.051

48. Billker O, Lourido S, Sibley LD. Calcium-dependent signaling and kinases in apicomplexan parasites. Cell Host Microbe (2009) 5:612–22. doi: 10.1016/j.chom.2009.05.017

49. Schubert U, Fuchs J, Zimmermann J, Jahn D, Zoufal K. Extracellular calcium deficiency and ryanodine inhibit Eimeria tenella sporozoite invasion in vitro. Parasitol Res. (2005) 97:59–62. doi: 10.1007/s00436-005-1388-5

50. Bilmen JG, Khan SZ, Javed M, Michelangeli F. Inhibition of the SERCA Ca\(^{2+}\) pumps by curcumin: curcumin putatively stabilizes the interaction between the nucleotide-binding and phosphorylation domains in the absence of ATP. Eur J Biochem. (2001) 268:6318–27. doi: 10.1046/j.0014-2956.2001.02589.x

51. Santos JM, Lebrun M, Daher W, Soldati D, Dubremetz JF. Apicomplexan cytoskeleton and motors: key regulators in morphogenesis, cell division, transport and motility. Int J Parasitol. (2009) 39:153–62. doi: 10.1016/j.ijpara.2008.10.007

52. Dubremetz JF, Garcia-Réguet N, Conseil V, Fourmaux MN. Apical organelles and host-cell invasion by Apicomplexa. Int J Parasitol. (1998) 28:1007–13.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Cervantes-Valencia, Hermosilla, Alcalá-Canto, Tapia, Taubert and Silva. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.